Pharmacoeconomic Analysis of Direct Activity Antiviral Drugs Used for Treatment of Genotype 1 Chronic Hepatitis C
Journal Title: Journal of Pharmaceutical Research International - Year 2016, Vol 13, Issue 2
Abstract
Aims: Hepatitis C is one of the most important global health care problems. The goal of this study was to perform a pharmacoeconomic analysis of therapeutic schemes used in treatment of patients with genotype 1 chronic HCV by using direct-acting antiviral agents in combination with pegylated interferons and ribavirin. Study Design: In the current study comparison of therapeutic schemes used in treatment of patients with genotype 1 chronic HCV by using direct-acting antiviral agents in combination with pegylated interferons and ribavirin was made. Place and Duration of Study: Moscow Institute of Physics and Technology (State University), Department of Biological and Medical Physics, Laboratory of government programs and development projects in life sciences (April 2015 - November 2015). Methodology: In the current study Markov decision process model was built in order to assess long-term costs and efficacy of preparations under study. Comparison of therapeutic schemes for chronic HCV infection treatment was performed with the use of cost-effectiveness and cost-utility analysis. In costs-effectiveness analysis, therapeutic schemes for CHC treatment that include telaprevir, boceprevir and simeprevir, life years gained (LYG) and quality adjusted life years (QALY) served as a criterion of benefit in costs-effectiveness and cost-utility analysis respectively. Results: Pharmacoeconomic analysis of treatment of chronic hepatitis C viral infection showed that the best combination of costs and effectiveness was observed in combined treatment with the use of pegylated interferon, ribavirin and boceprevir in treatment-naïve patients as well as patients with unsuccessful treatment experience. Conclusion: Our results showed that combined therapy with the use of boceprevir is the most pharmacoeconomically justified in comparison with telaprevir and simeprevir-based treatment.
Authors and Affiliations
N. Z. Musina, A. G. Savilova, O. M. Korzinov
Keywords
Related Articles
- EP ID EP342168
- DOI 10.9734/BJPR/2016/27144
- Views 78
- Downloads 0
Assessment of Analgesic and Neuropharmacological Activity of Different Extracts of Euphorbia hirta (Linn.) Leaf
Aims: The present study was carried out to investigate the possible analgesic and neuropharmacological activities of the aqueous, ethanol and ethyl acetate extracts of Euphorbia hirta (Linn.) leaves. Methods: The analge...
In vitro Antisalmonellal and Antioxidant Activities of the Crude Extracts and Fractions from the Stem Bark of Albizia gummifera (J. F. Gmel.) C. A. Sm.
Aims: Typhoid fever is an infectious disease, which continues to be a serious health problem and remains a major cause of morbidity and mortality in the developing country. Considering the ethnopharmacological relevance...
Molecular Characterization Using gtf Gene Detection and Medium Optimization of Beta-D-Glucan Production from Pediococcus parvulus F1030 Isolated from Local Egyptian Boza
Background: Lactic acid bacteria (LAB) have great benefits which can improve the nutritional value of food, reduces some infections, immune modulator effect, curbs some types of cancer and restricts glucose level of seru...
In vivo Antioxidant Activity and Anti Hyperglycemic Relevant Enzyme Inhibition Properties of Petroleum Ether Extract of Traditionaly Processed Ocimum canum Leaves
Objective: To investigate the antihyperglycemic and antioxidant properties of the petroleum ether extract of Ocimum canum leaves in streptozotocin-induced diabetic rats. Place and Duration of Study: Pinacle Biomedical Re...
Use of Hydrazine Carboxamide-2-[(2-Hydroxy-1- Naphthalenyl) Methylene] as an Analytical Reagent for the Extractive Spectrophotometric Determination of U(Vi)
Extraction and spectrophotometric determination of Uranium (VI) was carried out using Hydrazine Carboxamide-2-[(2-Hydroxy-1-Naphthalenyl) Methylene] as an analytical reagent. A reddish brown coloured complex is formed at...